Compare KALU & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KALU | IRON |
|---|---|---|
| Founded | 1946 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.6B |
| IPO Year | 2006 | 2020 |
| Metric | KALU | IRON |
|---|---|---|
| Price | $180.57 | $69.08 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $147.33 | $103.18 |
| AVG Volume (30 Days) | 262.7K | ★ 303.1K |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.78% | N/A |
| EPS Growth | ★ 135.89 | N/A |
| EPS | ★ 3.71 | N/A |
| Revenue | ★ $1,585,900,000.00 | N/A |
| Revenue This Year | $13.37 | N/A |
| Revenue Next Year | $2.62 | $283.52 |
| P/E Ratio | $48.54 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $70.40 | $40.00 |
| 52 Week High | $183.00 | $99.50 |
| Indicator | KALU | IRON |
|---|---|---|
| Relative Strength Index (RSI) | 72.09 | 56.63 |
| Support Level | $74.15 | $57.79 |
| Resistance Level | $181.47 | $69.36 |
| Average True Range (ATR) | 7.77 | 2.77 |
| MACD | 0.14 | -0.10 |
| Stochastic Oscillator | 91.35 | 52.30 |
Kaiser Aluminum Corp specializes in the production of semi-fabricated specialty aluminum mill products, such as aluminum plate and sheet, bare and coated coil and extruded and drawn products, for the end market applications: Aero/HS Products; Packaging; GE Products; and Automotive Extrusions. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from the United States.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs), including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.